GSK - Public offerings

CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced the closing of its previously announced exclusive license agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited (NYSE:GSK) (GSK) for tebipenem HBr, an investigational drug being developed as the potentially first oral carbapenem antibiotic for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by c

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that the exclusive license agreement between Arrowhead and GlaxoSmithKline (NYSE:GSK) announced on November 22, 2021, has now closed. Closing of the transaction was subject to customary closing conditions and expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be

Companies aim to develop a multi-valent candidate vaccine to address emerging variants for pandemic and endemic use Development to begin immediately targeting vaccine availability in 2022, subject to regulatory approval GSK will also support manufacture of up to 100 million doses of CureVac's first generation COVID-19 vaccine CVnCoV in 2021 LONDON, UK / TUBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / February 3, 2021 / GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq: CVAC) today announced a new €150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address m